Clinically relevant model of oxaliplatin‐induced sinusoidal obstruction syndrome
Hepatology Research · 2023-02 · 53 (2) · 145-159
DOI: 10.1111/hepr.13842 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatology Research, online erschienen am 06.10.2022. Verfasst von Rei Toda und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Aim
Sinusoidal obstruction syndrome (SOS) induced by oxaliplatin‐including chemotherapies (OXCx) is associated with impaired hepatic reserve and higher morbidity after hepatic resection. However, in the absence of an appropriate animal experimental model, little is known about its pathophysiology. This study aimed to establish a clinically relevant reproducible model of FOLFOX‐induced SOS and to compare the clinical/histopathological features between the clinical and animal SOS settings.
Methods
We performed clinical/pathological analyses of colorectal liver metastasis (CRLM) patients who underwent hepatectomy with/without preoperative treatment of FOLFOX ( n = 22/18). Male micro‐minipigs were treated with 50% of the standard human dosage of the FOLFOX regimen.
Results
In contrast to the monocrotaline‐induced SOS model in rats, hepatomegaly, ascites, congestion, and coagulative necrosis of hepatocytes were absent in patients with CRLM with OXCx pretreatment and OXCx‐treated micro‐minipigs. In parallel to CRLM cases with OXCx pretreatment, OXCx‐challenged micro‐minipigs exhibited deteriorated indocyanine green clearance, morphological alteration of liver sinusoidal endothelial cells, and upregulated matrix metalloproteinase‐9. Using our novel porcine SOS model, we identified the hepatoprotective influence of recombinant human soluble thrombomodulin in OXCx‐SOS.
Conclusions
With distinct differences between monocrotaline‐induced rat SOS and human/pig OXCx‐SOS, our pig OXCx‐SOS model serves as a preclinical platform for future investigations to dissect the pathophysiology of OXCx‐SOS and seek preventive strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Surgery, Kanazawa Medical University, Ishikawa, Japan.
- Department of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan.
- Department of Gastrointestinal Medicine & Surgery, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan.
- Department of Surgery, Kobe City Nishi-Kobe Medical Center, Kobe, Japan.
- Department of Clinical Pharmacology and Therapeutics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
ORCID-Profile: Rei Toda, Naohiko Nakamura
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Toda, R., Seo, S., Uemoto, Y., Morino, K., Nishino, H., Nakamura, N., Okuno, M., Iguchi, K., Sato, M., Nakamura, K., Taura, K., Nakagawa, S., Nakagawa, T., Tsuruyama, T., Manabe, T., Kawaguchi, H., Iwaisako, K., Ikegawa, M., Uemoto, S., & Hatano, E. (2023). Clinically relevant model of oxaliplatin‐induced sinusoidal obstruction syndrome. Hepatology Research, 53(2), 145-159. https://doi.org/10.1111/hepr.13842
Vancouver
Toda R, Seo S, Uemoto Y, Morino K, Nishino H, Nakamura N, et al. Clinically relevant model of oxaliplatin‐induced sinusoidal obstruction syndrome. Hepatology Research. 2023;53(2):145-159. doi:10.1111/hepr.13842
BibTeX
@article{Toda2023,
author = {Toda, Rei and Seo, Satoru and Uemoto, Yusuke and Morino, Koshiro and Nishino, Hiroto and Nakamura, Naohiko and Okuno, Masayuki and Iguchi, Kohta and Sato, Motohiko and Nakamura, Kojiro and Taura, Kojiro and Nakagawa, Shunsaku and Nakagawa, Takayuki and Tsuruyama, Tatsuaki and Manabe, Toshiaki and Kawaguchi, Hiroaki and Iwaisako, Keiko and Ikegawa, Masaya and Uemoto, Shinji and Hatano, Etsuro},
title = {Clinically relevant model of oxaliplatin‐induced sinusoidal obstruction syndrome},
journal = {Hepatology Research},
year = {2023},
volume = {53},
number = {2},
pages = {145--159},
doi = {10.1111/hepr.13842}
}
EUVIMED